74P - The influence of genetic phenotype on prognosis of osteosarcoma

Background

To study tumor’s genetic phenotype in patients with osteosarcoma and estimate long-term results.

Methods

221 patients with osteosarcoma were included to research. The gender ratio was 133 men, 88 women. The age of patients was from 1 to 35 years. The distribution of patients by localization of tumor was as follows: in 102 patients femoral bone damaged by tumor, in 83 patients – in tibialis, in 16 patients – in fibula, in 11 patients in the radial bone, in 6 patients - in iliac bone, and 5 in the humerus. In all cases, the treatment was performed according to the protocol and treatment standard. The tumor markers (P53; Ki67; BcL2) were studied by the method of immunohistochemistry. The combination of P53 + / Ki67 + / Bcl2 - was considered as a negative combination and the combination of P53 - / Ki67- / Bcl2+ as a positive. Depending on the combination of genetic markers, the survival rate of patients was studied by method of Kaplan-Meier.

Results

The 3 and 5-year survival rates of patients with osteosarcoma who had a positive combination of genetic markers (40.0% and 0%) was lower than patients who had negative P53 - / Ri67 - /Bcl2 + (90.0 ± 2.9% and 40.0 ± 4.2%) (P < 0.05). The 3 and 5-year survival rates without metastasis in adverse gene combinations of P53 + / Ki67 + / Bcl2 + was 70.0 ± 3.4% and 10.0 ± 3.2%, while the positive phenotype was - 90.0 ± 3.4% and 50.0 ± 4.3% (P < 0.05). In the analysis, the 3 and 5 year survival rates without recurrent in the negative phenotype was 60.0 ± 4.9% and 10.0 ±4%, whereas in a positive it was 90.03 ± 3.2% and 50.0 ± 4.2% (P < 0.05).

Conclusions

The research shown that, the forecast was adverse in the positive expression of P53+/Ki67+. The tactics in the treatment of osteosarcoma can be changed by combination of these markers.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

N.S. Kamalovich.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.